Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development

Drug Metabolism Reviews

Volumn 45, Issue 1, 2013, Pages 3-14

  Sinz, Michael W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Agonist; Induction; Liability; Screening; Transactivation

Indexed keywords

CARBAMAZEPINE; HYPERFORIN; PREGNANE X RECEPTOR; PREGNENOLONE DERIVATIVE; RIFAMPICIN; SR 12813; UNCLASSIFIED DRUG;

DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYTOCHROME P-450 CYP3A; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; RECEPTORS, STEROID; TRANSCRIPTIONAL ACTIVATION;

EID: 84872704323     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2012.743560     Document Type: Review

References (51)

1. Ai, N., Krasowski, M. D., Welsh, W. J., Ekins, S. (2009). Understanding nuclear receptors using computational methods. Drug Discov Today 14: 486-494.
2. Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., et al. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95: 12208-12213. (Pubitemid 28483744)
3. Bertilsson, L., Hojer, B., Tybring, G., Osterloh, J., Rane, A. (1980). Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27: 83-88. (Pubitemid 10096585)
4. Blumberg, B., Evans, R. M. (1998). Orphan nuclear receptors-new ligands and new possibilities. Genes Dev 12: 3149-3155. (Pubitemid 28496259)
5. Carnahan, V. E., Redinbo, M. R. (2005). Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 6: 357-367. (Pubitemid 41086768)
6. Chu, V., Einolf, H. J., Evers, R., Kumar, G., Moore, D., Ripp, S., et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 37: 1339-1354.
7. Cui, X., Thomas, A., Gerlach, V., White, R. E., Morrison, R. A., Cheng, K. C. (2008). Application and interpretation of hPXR screening data: validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem Pharmacol 76: 680-689.
8. Ekins, S., Chang, C., Mani, S., Krasowski, M. D., Reschly, E. J., Iyer, M., et al. (2007). Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72: 592-603. (Pubitemid 47347294)
9. El-Sankary, W., Gibson, G. G., Ayrton, A., Plant, N. (2001). Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29: 1499-1504. (Pubitemid 33000699)
10. EMA. (2012). Guideline on the investigation of drug interactions. Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 07/WC500129606.pdf. Accessed on September XX, 2012.
11. Enoru-Eta, J., Yengi, L. G., He, X., Kubik, J., Kao, J., Scatina, J. (2010). Development of a UGT1A1 reporter gene assay for induction studies: correlation between reporter gene data and regulation of UGT1A1 in human hepatocytes. Drug Metab Lett 4: 31-38.
12. Fahmi, O. A., Ripp, S. L. (2010). Evaluation of models for predicting drug-drug interactions due to induction. Expert Opin Drug Metab Toxicol 6: 1399-1416.
13. FDA. (2012). Guidance for industry: drug interaction studies-study design, data analysis,implications for dosing, and labeling recommendations. Guidance for industry: drug interaction studies-study design, data analysis,implications for dosing, and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf.
14. Fotsch, C., Bartberger, M. D., Bercot, E. A., Chen, M., Cupples, R., Emery, M., et al. (2008). Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J Med Chem 51: 7953-7967.
15. Gao, Y. D., Olson, S. H., Balkovec, J. M., Zhu, Y., Royo, I., Yabut, J., et al. (2007). Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37: 124-138.
16. Gonzalez, F. J., Yu, A. M. (2006). Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46: 41-64. (Pubitemid 43271183)
17. Hariparsad, N., Carr, B. A., Evers, R., Chu, X. (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36: 1046-1055. (Pubitemid 351717461)
18. Harper, S., Avolio, S., Pacini, B., Di Filippo, M., Altamura, S., Tomei, L., et al. (2005). Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 48: 4547-4557. (Pubitemid 40993416)
19. Hasegawa, M., Kapelyukh, Y., Tahara, H., Seibler, J., Rode, A., Krueger, S., et al. (2011). Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80: 518-528.
20. Hewitt, N. J., De Kanter, R., Lecluyse, E. (2007). Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry-do they comply with FDA recommendations? Chem Biol Interact 168: 51-65. (Pubitemid 46659920)
21. Jeong, H., Choi, S., Song, J. W., Chen, H., Fischer, J. H. (2008). Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38: 62-75.
22. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., Mckee, D. D., et al. (2000). The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14: 27-39. (Pubitemid 32260325)
23. Khandelwal, A., Krasowski, M. D., Reschly, E. J., Sinz, M. W., Swaan, P. W., Ekins, S. (2008). Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21: 1457-1467.
24. Kim, S., Dinchuk, J. E., Anthony, M. N., Orcutt, T., Zoeckler, M. E., Sauer, M. B., et al. (2010). Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 38: 16-24.
25. Kim, S., Pray, D., Zheng, M., Morgan, D. G., Pizzano, J. G., Zoeckler, M. E., et al. (2008). Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential. Drug Metab Lett 2: 169-175.
26. Kliewer, S. A., Goodwin, B., Willson, T. M. (2002). The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23: 687-702. (Pubitemid 35191629)
27. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82. (Pubitemid 28053299)
28. Lemaire, G., Benod, C., Nahoum, V., Pillon, A., Boussioux, A. M., Guichou, J. F., et al. (2007). Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol Pharmacol 72: 572-581. (Pubitemid 47347292)
29. Li, L., Sinz, M. W., Zimmermann, K., Wang, H. (2012). An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J Pharmacol Exp Ther 340: 688-697.
30. Matter, H., Anger, L. T., Giegerich, C., Gussregen, S., Hessler, G., Baringhaus, K. H. (2012). Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules. Bioorg Med Chem 20: 5352-5365.
31. Mcginnity, D. F., Zhang, G., Kenny, J. R., Hamilton, G. A., Otmani, S., Stams, K. R., et al. (2009). Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37: 1259-1268.
32. Nishimura, M., Koeda, A., Suganuma, Y., Suzuki, E., Shimizu, T., Nakayama, M., et al. (2007). Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet 22: 178-186.
33. Park, J. Y., Kim, K. A., Kang, M. H., Kim, S. L., Shin, J. G. (2004). Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 75: 157-162.
34. Prueksaritanont, T., Kuo, Y., Tang, C., Li, C., Qiu, Y., Lu, B., et al. (2006). In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34: 1546-1555. (Pubitemid 44285397)
35. Raucy, J. L., Lasker, J. M. (2010). Current in vitro high throughput screening approaches to assess nuclear receptor activation. Curr Drug Metab 11: 806-814.
36. Rew, Y., McMinn, D. L., Wang, Z., He, X., Hungate, R. W., Jaen, J. C., et al. (2009). Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 19: 1797-1801.
37. Schlegel, K. A., Yang, Z. Q., Reger, T. S., Shu, Y., Cube, R., Rittle, K. E., et al. (2010). Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. Bioorg Med Chem Lett 20: 5147-5152.
38. Simonsson, U. S., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., Ashton, M. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74: 32-43. (Pubitemid 36776174)
39. Sinz, M., Kim, S. (2006). Stem cells, immortalized cells, and primary cells in ADMET assays. Drug Discov Today Technol 3: 79-85.
40. Sinz, M., Kim, S., Zhu, Z., Chen, T., Anthony, M., Dickinson, K., Rodrigues, A. D. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7: 375-388.
41. Sinz, M., Wallace, G., Sahi, J. (2008). Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10: 391-400.
42. Tolson, A. H., Wang, H. (2010). Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62: 1238-1249.
43. Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., et al. (2003). 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42: 1430-1438. (Pubitemid 36205949)
44. Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., et al. (2001). The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329-2333. (Pubitemid 32568055)
45. Wipf, P., Gong, H., Janjic, J. M., Li, S., Day, B. W., Xie, W. (2007). New opportunities for pregnane X receptor (PXR) targeting in drug development. Lessons from Enantio-and species-specific PXR ligands identified from a discovery library of amino acid analogues. Mini Rev Med Chem 7: 617-625. (Pubitemid 47099182)
46. Worboys, P. D., Carlile, D. J. (2001). Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica 31: 539-556. (Pubitemid 32826391)
47. Xue, Y., Moore, L. B., Orans, J., Peng, L., Bencharit, S., Kliewer, S. A., et al. (2007). Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 21: 1028-1038. (Pubitemid 46984756)
48. Zhou, C., Verma, S., Blumberg, B. (2009). The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 7: e001.
49. Zhu, Z., Kim, S., Chen, T., Lin, J. H., Bell, A., Bryson, J., et al. (2004). Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9: 533-540.
50. Zhu, Z., Puglisi, J., Connors, D., Stewart, J., Herbst, J., Marino, A., et al. (2007). Use of cryopreserved transiently transfected cells in highthroughput pregnane X receptor transactivation assay. J Biomol Screen 12: 248-254. (Pubitemid 46364431)
51. Zimmermann, K., Wittman, M. D., Saulnier, M. G., Velaparthi, U., Sang, X., Frennesson, D. B., et al. (2010). SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett 20: 1744-1748.